Gabelli Funds LLC trimmed its holdings in shares of Pfizer (NYSE:PFE) by 14.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,059,224 shares of the biopharmaceutical company’s stock after selling 182,324 shares during the period. Gabelli Funds LLC’s holdings in Pfizer were worth $38,365,000 as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of the business. Beach Investment Management LLC. bought a new position in shares of Pfizer in the 2nd quarter worth $5,214,000. Hanson McClain Inc. lifted its holdings in shares of Pfizer by 2.0% in the 2nd quarter. Hanson McClain Inc. now owns 13,898 shares of the biopharmaceutical company’s stock worth $467,000 after purchasing an additional 276 shares in the last quarter. Alpha Omega Wealth Management LLC lifted its holdings in shares of Pfizer by 3.4% in the 2nd quarter. Alpha Omega Wealth Management LLC now owns 108,815 shares of the biopharmaceutical company’s stock worth $3,655,000 after purchasing an additional 3,534 shares in the last quarter. Usca Ria LLC lifted its holdings in shares of Pfizer by 0.3% in the 2nd quarter. Usca Ria LLC now owns 332,964 shares of the biopharmaceutical company’s stock worth $11,184,000 after purchasing an additional 1,033 shares in the last quarter. Finally, Intrust Bank NA lifted its holdings in shares of Pfizer by 2.5% in the 2nd quarter. Intrust Bank NA now owns 65,268 shares of the biopharmaceutical company’s stock worth $2,192,000 after purchasing an additional 1,596 shares in the last quarter. Hedge funds and other institutional investors own 71.21% of the company’s stock.
In other news, Director W Don Cornwell sold 1,758 shares of the firm’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $36.79, for a total transaction of $64,676.82. Following the completion of the sale, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $36,790. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Sally Susman sold 33,368 shares of the firm’s stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $37.03, for a total value of $1,235,617.04. Following the sale, the executive vice president now directly owns 191,505 shares of the company’s stock, valued at $7,091,430.15. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 248,037 shares of company stock worth $9,064,785. Company insiders own 0.06% of the company’s stock.
Shares of NYSE:PFE opened at $36.32 on Monday. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47. Pfizer has a 1-year low of $31.67 and a 1-year high of $39.43. The firm has a market cap of $216,208.05, a price-to-earnings ratio of 13.71, a P/E/G ratio of 1.81 and a beta of 0.90.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The business had revenue of $13.70 billion for the quarter, compared to analysts’ expectations of $13.67 billion. During the same period last year, the business earned $0.47 EPS. The business’s revenue was up .6% on a year-over-year basis. sell-side analysts forecast that Pfizer will post 2.96 earnings per share for the current year.
Pfizer announced that its Board of Directors has initiated a stock repurchase plan on Monday, December 18th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares buyback plans are often an indication that the company’s board of directors believes its stock is undervalued.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.